ClinicalTrials.gg
Status unknownNCT03425240Updated Feb 8, 2018

Intra-operative Neuromodulation of the Pelvic Plexus

An interventional study of Nerve Stimulation in Erectile Dysfunction and Prostate Cancer, sponsored by Laikο General Hospital, Athens. Status unknown at 1 site in Greece. Open to male participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-02-08.

Sponsored by Laikο General Hospital, Athens · Not applicable, Interventional, and Device feasibility

The sponsor has not verified this record recently (last verified Feb 2018), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 3 years 4 months after the study started (first participant enrolled Sep 2014, registered Jan 2018).
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
40 Years to 75 Years
Sex
Male
01

Study summary

The purpose of this study is to evaluate the feasibility of electrical stimulation of nerves responsible for erectile function to evoke penile erection after surgery to remove the prostate (prostatectomy).

Read the detailed description

Prostate cancer is the main cancer in men. However, the survival rate for clinically localized prostate cancer is prominent mainly due to radical prostatectomy (RP), the gold standard treatment for non-metastatic cancers. Unfortunately, despite providing optimal cancer control, RP often lead to neuropraxia and persistent erectile dysfunction in approximately 80% of men 1 year after prostatectomy. Various erectile rehabilitation strategies have not been able to prove a beneficial action yet. However, electrical stimulation has been demonstrated to favour neuroregeneration and the functional recovery of neuromuscular systems and has been shown to induce and maintain penile erection in animals and humans. Therefore, electrical stimulation of the pelvic plexus nerves during radical prostatectomy is being investigated for its potential development into a treatment aimed at improving recovery of erectile function after prostatectomy.

The primary objective of this study is to explore the feasibility of using a neurostimulation device post radical prostatectomy as a method for neurogenic erectile dysfunction treatment. During standard open radical prostatectomy, the pelvic plexus nerves will be electrically stimulated intraoperatively and the modification of penile circumference will be recorded.

The secondary objective is to assess proper placement of the stimulation electrodes and stimulation parameters needed to achieve maximal change in penile circumference.

02

Conditions studied

  • Erectile Dysfunction
  • Prostate Cancer

Keywords

  • Erectile Dysfunction
  • Prostate Cancer
  • Neuromodulation
03

In context

Erectile Dysfunction

701 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.

This study's planned enrollment of 20 is below the median of 70 across 551 interventional studies indexed under Erectile Dysfunction.

Browse Erectile Dysfunction studies →

Lead sponsor

Laikο General Hospital, Athens is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Scheduled for open radical prostatectomy procedure under total anesthesia.
  • Age 40 to 75 years old.
  • Able to read and understand patient information materials and willing to sign a written .

Exclusion criteria

Exclusion Criteria:

  • Have been diagnosed with severe vasculogenic erectile dysfunction.
  • Have a prior history of pelvic surgery, trauma or irradiation therapy.
  • Have a penile prosthesis.
  • Have been diagnosed with neurologic diseases that may negatively impact erectile functions.
  • Currently having an active implantable device (such as a pacemaker).
  • Posses any other characteristics that, per the investigator's judgment, may increase the risk or impair data collection for the procedure/study.
  • Inability to provide a fully .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Nerve Stimulation

    Acute placement of electrodes and electrostimulation of the pelvic plexus nerves during open radical prostatectomy.

    Device: Nerve Stimulation

Interventions

  • DeviceNerve Stimulation

    Acute placement of electrodes on the pelvic plexus to apply electrostimulation during open radical prostatectomy.

06

What researchers measure

Primary outcomes

  1. Penile circumference increase in millimeters.

    Change in penile circumference \[mm\] in response to electrical stimulation of the pelvic plexus nerves measured by a penile plethysmograph.

    Time frame: 5 minutes

Secondary outcomes

  1. Anatomic location of stimulation site

    The anatomic location of the stimulation site on the pelvic floor (determined by the surgeon).

    Time frame: 5 to 15 minutes

  2. Stimulation threshold in volts

    Amplitude in volts of the electrical stimulation pulses to induce penile response.

    Time frame: 5 to 15 minutes

07

Study locations

1 of 1 sites recruiting
  • Laikon General Hospital of Athens
    Athens, 11527, Greece
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2014 (actual). Primary completion is estimated for Dec 2018, 51 months after the start.

Of 115 non-industry interventional studies with no phase under Erectile Dysfunction, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 52. This study's planned 51 months is above that.

Counting every sponsor, half of 137 studies reached it within 32 months; a quarter within 14 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2018
First posted
Feb 7, 2018
StartActual
Sep 10, 2014
Primary completionEst.
Dec 2018
CompletionEst.
Dec 2018
Last update
Feb 8, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03425240
Lead sponsor
Laikο General Hospital, Athens
Responsible party
Dr. Ioannis Adamakis (MD, Principal investigator, Laikο General Hospital, Athens) — Principal investigator
First posted
Feb 7, 2018
Start date
Sep 10, 2014
Primary completion
Dec 2018 (estimated)
Completion
Dec 2018 (estimated)
Last update
Feb 8, 2018

Study contacts

Spyridon Skoufias, MD
Contact
spyskouf@hotmail.com
spyskouf@hotmail.com
Ioannis Adamakis, MD
principal investigator · Laikon General Hospital of Athens
Constantinos A. Constantinides, MD
study chair · Laikon General Hospital of Athens

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion